Riad Mishlawi - Hikma Pharmaceuticals EU Vice President and Global Head - Injectables
| HKMPY Stock | USD 46.50 0.00 0.00% |
President
Mr. Riad Mishlawi is CEO, Injectables Division of the Company. Riad is responsible for all aspects of the Injectables division globally. Riad has significant pharmaceutical and operational experience from leadership roles at Hikma and Watson Pharmaceuticals. BSc in Engineering and a Masters in Engineering and Management from George Washington University. since 2017.
| Tenure | 7 years |
| Phone | 44 20 7399 2760 |
| Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Aristippos Gennadios | Catalent | 58 | |
| Rajiv Malik | Viatris | 63 | |
| Mark McKenna | Bausch Health Companies | 38 | |
| Steven Fasman | Catalent | 57 | |
| Scott Gunther | Catalent | 52 | |
| Wetteny Joseph | Catalent | 48 | |
| Christina Ackermann | Bausch Health Companies | 55 | |
| Alessandro Maselli | Catalent | 52 | |
| Kristina Adamski | Tilray Inc | N/A | |
| Lance Miyamoto | Catalent | 62 | |
| Anthony Mauro | Viatris | 51 | |
| Ricky Hopson | Catalent | 47 | |
| Christine Dolan | Catalent | 49 | |
| Paul Herendeen | Bausch Health Companies | 65 | |
| Ricardo Pravda | Catalent | 48 | |
| Scott Houlton | Catalent | 47 | |
| Charles Lickfold | Catalent | 50 | |
| Barry Littlejohns | Catalent | 51 | |
| Jonathan Arnold | Catalent | 54 | |
| Aris Gennadios | Catalent | 49 | |
| Joseph Gordon | Bausch Health Companies | 56 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
| Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
| Khalid Nabilsi, Chief Officer | ||
| Hussein Arkhagha, General Counsel | ||
| Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
| Pamela Kirby, Non-Executive Independent Director | ||
| John Castellani, Non-Executive Independent Director | ||
| Brian Hoffman, President and Chief Executive of - Generics Division | ||
| Ali AlHusry, Non-Executive Director | ||
| Jochen Gann, Non-Executive Director | ||
| Engineer Darwazah, Ex CEO | ||
| Peter Speirs, Company Secretary | ||
| Patrick Butler, Non-Executive Independent Director | ||
| Brian Hoffmann, Pres Generics | ||
| Said Darwazah, Chairman and CEO | ||
| Michael Raya, President and CEO, USA | ||
| Samuel Park, Global US | ||
| Ronald Goode, Non-Executive Independent Director | ||
| Bryan Hotston, CIO | ||
| Sigurdur Olafsson, CEO | ||
| Breffni Byrne, Non-Executive Independent Director | ||
| Nina Henderson, Non-Executive Independent Director | ||
| Cynthia Schwalm, Independent Non-Executive Director | ||
| Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
| Michael Ashton, Non-Executive Independent Director | ||
| Majda Labadi, Corporate Vice President - Human Resources | ||
| Ibrahim Jalal, Sr. Corporate VP of Technical Affairs | ||
| Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
| Robert Pickering, Senior Non-Executive Independent Director | ||
| Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
| CPA CFA, Exec MA |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 110.13 M | |||
| Price To Earning | 10.10 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 2.55 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |